Vectormune ND


Newcastle disease and Marek’s disease vaccine (live recombinant)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Vectormune ND. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Vectormune ND.

For practical information about using Vectormune ND, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 06/09/2021

Authorisation details

Product details
Vectormune ND
Agency product number
Active substance
cell-associated live recombinant turkey herpes virus (rHVT/ND) expressing the fusion protein of Newcastle diseases virus D-26 lentogenic strain
International non-proprietary name (INN) or common name
Newcastle disease and Marek’s disease vaccine (live recombinant)
  • Chicken
  • Embryonated eggs
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
CEVA-Phylaxia Co. Ltd.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Szállás u. 5.
1107 Budapest

Product information

17/02/2021 Vectormune ND - EMEA/V/C/003829 - WS/1892

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for aves

  • Live viral vaccines

Therapeutic indication

For active immunisation of 18 day-old embryonated chicken eggs or one-day-old chicks to reduce mortality and clinical signs caused by Newcastle disease virus and to reduce mortality, clinical signs and lesions caused by Marek’s disease virus with a phenotype "virulent".

Assessment history


How useful was this page?

Add your rating